Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, … Read more
Xlife Sciences AG (XLS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.003x
Based on the latest financial reports, Xlife Sciences AG (XLS) has a cash flow conversion efficiency ratio of -0.003x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-803.62K) by net assets (CHF303.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xlife Sciences AG - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Xlife Sciences AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xlife Sciences AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xlife Sciences AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CBAK Energy Technology Inc
NASDAQ:CBAT
|
0.123x |
|
AFFINITY BANCSHS DL-01
F:5610
|
N/A |
|
Digital Daesung Co. Ltd
KQ:068930
|
0.099x |
|
Sound Financial Bancorp Inc
NASDAQ:SFBC
|
0.035x |
|
Voss Veksel og Landmandsbank ASA
OL:VVL
|
0.227x |
|
Tempo Scan Pacific Tbk
JK:TSPC
|
0.035x |
|
Eucatex S.A. Indústria e Comércio
SA:EUCA3
|
0.058x |
|
Anadolu Isuzu Otomotiv Sanayi ve Ticaret AS
IS:ASUZU
|
-0.048x |
Annual Cash Flow Conversion Efficiency for Xlife Sciences AG (2019–2024)
The table below shows the annual cash flow conversion efficiency of Xlife Sciences AG from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CHF305.26 Million | CHF-421.51K | -0.001x | -315.57% |
| 2023-12-31 | CHF268.17 Million | CHF171.78K | 0.001x | +103.27% |
| 2022-12-31 | CHF235.23 Million | CHF-4.61 Million | -0.020x | +4.32% |
| 2021-12-31 | CHF211.23 Million | CHF-4.32 Million | -0.020x | -563.59% |
| 2020-12-31 | CHF130.17 Million | CHF-401.55K | -0.003x | +24.57% |
| 2019-12-31 | CHF97.38 Million | CHF-398.24K | -0.004x | -- |